The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
出版年份 2019 全文链接
标题
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-12-06
DOI
10.3389/fonc.2019.01366
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
- (2019) Yuna Blum et al. Nature Communications
- Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays
- (2019) David B. Chapel et al. HUMAN PATHOLOGY
- NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
- (2019) Rosa Sottile et al. INTERNATIONAL JOURNAL OF CANCER
- A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
- (2019) Emilie M. J. van Brummelen et al. INVESTIGATIONAL NEW DRUGS
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion
- (2019) Pietro Bertino et al. OncoImmunology
- LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2019) S Popat et al. ANNALS OF ONCOLOGY
- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
- (2018) Aliya Noor Husain et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
- (2018) Swati Khanna et al. CLINICAL CANCER RESEARCH
- Metabolic Barriers to T Cell Function in Tumors
- (2018) Ayaka Sugiura et al. JOURNAL OF IMMUNOLOGY
- Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
- (2018) Namrata S. Patil et al. Journal of Thoracic Oncology
- How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations
- (2018) Hubert Rehrauer et al. ONCOGENE
- Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
- (2018) Ian Woolhouse et al. THORAX
- Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications
- (2018) Sophia Magkouta et al. Oncotarget
- Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
- (2018) Takuya Watanabe et al. Oncotarget
- Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization
- (2018) Annalisa Bosi et al. Journal of Immunology Research
- Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma
- (2018) Myung-Chul Kim et al. BMC CANCER
- Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).
- (2018) Arpita Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
- (2018) Yannis Metaxas et al. Journal of Thoracic Oncology
- Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo
- (2018) Chang Li et al. Scientific Reports
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
- (2018) Xian Shen et al. BMJ-British Medical Journal
- VISTA expressed in tumour cells regulates T cell function
- (2018) Kumuluzi Mulati et al. BRITISH JOURNAL OF CANCER
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Turning foes to friends: targeting cancer-associated fibroblasts
- (2018) Xueman Chen et al. NATURE REVIEWS DRUG DISCOVERY
- Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types
- (2018) Marcella Tazzari et al. Journal of Immunology Research
- Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
- (2018) Aaron S. Mansfield et al. Journal of Thoracic Oncology
- P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress
- (2017) Wei-Sen Lam et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
- (2017) Elly Marcq et al. Oncotarget
- The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
- (2017) Christian M. Schürch et al. OncoImmunology
- Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
- (2017) Kazuma Kiyotani et al. OncoImmunology
- c-Met expression and MET amplification in malignant pleural mesothelioma
- (2016) Melanie C. Bois et al. Annals of Diagnostic Pathology
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions
- (2016) Rajesh Thomas et al. CHEST
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
- (2016) Anne-Laure Chéné et al. Journal of Thoracic Oncology
- Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression
- (2016) Lysanne A. Lievense et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
- (2016) M. M. Awad et al. Cancer Immunology Research
- Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma
- (2016) Abdullah Cetin Tanrikulu et al. Environmental Health and Preventive Medicine
- Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
- (2016) Elly Marcq et al. OncoImmunology
- PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
- (2016) Rajani Kanteti et al. Scientific Reports
- Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales
- (2015) P. Beckett et al. LUNG CANCER
- Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT
- (2015) Roslyn J. Francis et al. LUNG CANCER
- Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
- (2015) Atsushi Mitsuhashi et al. Nature Communications
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
- (2015) Hideki Ujiie et al. OncoImmunology
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
- (2015) Iris Chiara Salaroglio et al. Oncotarget
- Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy
- (2014) Karin Schelch et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area
- (2014) Manola Comar et al. PLoS One
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation
- (2014) M Cioce et al. Cell Death & Disease
- Comparative Immunohistochemical Analysis of IMP3, GLUT1, EMA, CD146, and Desmin for Distinguishing Malignant Mesothelioma From Reactive Mesothelial Cells
- (2013) Hiroshi Minato et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study
- (2013) J. Hommell-Fontaine et al. ANNALS OF SURGICAL ONCOLOGY
- Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid
- (2013) Arnaud Scherpereel et al. BMC CANCER
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
- (2013) Petra C Schuberth et al. Journal of Translational Medicine
- NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation
- (2012) Paola Vacca et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase
- (2012) Connie Jackaman et al. INTERNATIONAL IMMUNOLOGY
- TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
- (2012) Makiko Fujii et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
- (2012) Christophe Blanquart et al. Journal of Thoracic Oncology
- Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network
- (2011) Qi Li et al. AMERICAN JOURNAL OF PATHOLOGY
- Identification of Novel Markers for the Diagnosis of Malignant Pleural Mesothelioma
- (2011) Fabien Gueugnon et al. AMERICAN JOURNAL OF PATHOLOGY
- Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma
- (2011) Bryan M. Burt et al. CANCER
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
- (2011) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
- (2011) Thierry Jahan et al. LUNG CANCER
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Macrophage Expression of Hypoxia-Inducible Factor-1 Suppresses T-Cell Function and Promotes Tumor Progression
- (2010) A. L. Doedens et al. CANCER RESEARCH
- Transforming growth factor-beta 1 (TGF-β1)- and β2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer
- (2010) J. MAEDA et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
- (2010) S. C. H. Kao et al. CLINICAL CANCER RESEARCH
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
- (2010) Cesar A. Corzo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma
- (2010) Tong Li et al. JOURNAL OF PATHOLOGY
- Asbestos, carbon nanotubes and the pleural mesothelium: a review and the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma
- (2010) Ken Donaldson et al. Particle and Fibre Toxicology
- Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
- (2010) Haining Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?☆
- (2010) Marco Lucchi et al. Interactive Cardiovascular and Thoracic Surgery
- Clinical Impact and Reliability of Pleural Fluid Mesothelin in Undiagnosed Pleural Effusions
- (2009) Helen E. Davies et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells
- (2009) C. Jackaman et al. EUROPEAN RESPIRATORY JOURNAL
- Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor
- (2009) Greta Alì et al. Journal of Thoracic Oncology
- Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target
- (2009) Stefania Crispi et al. PLoS One
- Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
- (2008) Masaki Anraku et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma
- (2008) N. R. Miselis et al. MOLECULAR CANCER THERAPEUTICS
- EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
- (2007) H Kothmaier et al. THORAX
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search